The Book of Pharmaceutical and Healthcare Lists
Albert Wertheimer, Richard Levy and Leo L.H. Lui Paperback
Now available as an eBook from Amazon>>
Information is the life blood of the pharmaceutical industry. Companies rely heavily on massive volumes of data to demonstrate the safety and efficacy of medicines submitted for registration, monitor adverse events and side-effects under strict post-marketing surveillance requirements, certify the cost effective performance of marketed products in improving public health outcomes, and protect patents, trademarks and other forms of intellectual property.
The challenge, however, is finding ways to make all this information accessible to others. The Book of Pharmaceutical and Healthcare Lists is the accessible answer to this essential question, serving as the entry point for anyone – from researchers to journalists to the general public, including patients – who needs help in transforming data and information into knowledge. It includes over 150 lists covering virtually every aspect of today’s biopharmaceutical business model, regulatory and policy arena, including worldwide health statistics, data on global pharmaceutical markets and marketing, and pharmaceutical and biotechnology innovation, as well as data on medication use and expenditures among the US population.
It is a reference source with diverse practical uses – from reinforcing the findings of a peer-reviewed clinical study, to providing background information and facts for journalists and speechwriters, marketers and advertisers, as well as students in public health, health administration and health policy.
Table of Contents
Table of Contents
Chapter 1. Pharmaceutical and Biotechnology Company Statistics
Overview 1
Pharmaceutical Companies
Table 1.1. The 12 Largest Pharmaceutical Companies ranked by Revenue
as of March 2010 according to their 2009 Annual Reports
Table 1.2. The 12 Largest Pharmaceutical Companies ranked by Revenue
as of July 2009 in the Fortune Global 500
Table 1.3. The 49 Largest Biopharmaceutical Companies, ranked by
Healthcare Revenue as of 2008
Table 1.4. Top 20 Global Corporations: Changes in sales from 2007 to 2012
Table 1.5. Top 20 U.S. Companies by non-discounted spending in
U.S. Market, 2008-2012
Table 1.6. Listing of all Pharmaceutical Companies having articles in Wikipedia
Table 1.7. PhRMA Companies: Names, Addresses, Phone numbers
Biotechnology Companies
Table 1.8. Biotechnology Industry: Size in Four Global Regions
Table 1.9. Independent Biotechnology Companies (2013)
Table 1.10. Biotechnology Companies Worldwide (BIO members) Generic
Drug Companies
Table 1.11. Top 10 Generic Pharmaceutical Companies, by 2010 Revenue
Mergers and Acquisitions
Table 1.12. Pharmaceutical Company Mergers 46
Table 1.13. Examples of Recent Acquisitions (2010-2013)
Table 1.14. Notable Acquisitions and Partnerships Involving Biologics
Employment in U.S. Pharmaceutical and Medicine Manufacturing Industries
Table 1.15. Employment of Wage and Salary Workers in Pharmaceutical
and Medicine Manufacturing, 2008 and Projected Change, 2008-2018
Table 1.16. Median Hourly Wages of the Largest Occupations in Pharmaceutical
and Medicine Manufacturing, May 2008
Chapter 2. Pharmaceutical Markets and Marketing
Overview
Global Markets
Table 2.1. Global Pharmaceutical Market, 2003- 2012
Table 2.2. Global Pharmaceutical Market by Region, 2012 – 2017
Table 2.3. Changes in World Ranking of Pharmaceutical Markets,
Projected, 2009-2013
Table 2.4. Top 20 Therapeutic Classes, Global Market, 2008-2012
Table 2.5. Top 20 Biopharmaceuticals Worldwide, ranked by 2012
Global Sales Estimate
Table 2.6. Top 15 Specialty Products (Global Sales), 2008 – 2009
Table 2.7. All-time Biggest Blockbusters (Global Sales)
Table 2.8. The World Health Organization (WHO) List of Essential Medicines
U.S Markets
Table 2.9. Top Medicines by Non-Discounted Spending (U.S.), 2008-2012
Table 2.10. Channel Distribution by Non-Discounted Spending (U.S.), 2008-2012
Table 2.11. Channel Distribution by Dispensed Prescriptions (U.S.), 2008-2012
Table 2.12. Retail Sales for Prescription Drugs Filled at U.S. Pharmacies, 2011
Table 2.13. Top Therapeutic Classes by Dispensed Prescriptions (U.S.), 2008-2012
Table 2.14. Top 25 Medicines by Dispensed Prescriptions (U.S.), 2008-2012
Table 2.15. Dispensing by Payment Type (U.S.), 2008-2012
Generic Drug Markets
Table 2.16. Generic Drugs: 10 Top World Market Sales, 2012 and Growth, 2008-2012
Table 2.17. Top Generics Companies: Market Share of World Generics Market, 2009
Table 2.18. Utilization of Generic Medicines within the Unprotected Markets, 2009
Table 2.19. Average Prescription Prices for Generic and Brand-Name Drugs, 2000-2010
Table 2.20. Billion Dollar Generics: Top 20 Generic Molecules Worldwide, 2011
Table 2.21. Drug Patent Expirations, 2013-2021
Table 2.22. The Biologics Patent Cliff
Promotional Spend
Table 2.23. Total U.S. Promotional Spend, by Type, 2007-2011
Table 2.24. Professional Detailing Spend, Journal Ad Spending, Professional
Meetings Spend, by Company, 2007-2008
Table 2.25. Total Promotional Spend, DTC Spend, E-promotional Spend,
by Company, 2007-2008
Table 2.26. Guidelines and Codes of Conduct for Marketing and Promotion
Established by Pharmaceutical Organizations
Chapter 3. Pharmaceutical and Biotechnology Innovation
Overview
Clinical Trials
Table 3.1. Attrition of Study Participants at Progressive Phases of
Clinical Trial Development
Table 3.2. Success Rates of Drugs by Therapeutic Class for Self-originated
Compounds First Tested in Humans from 1993 to 2004
Table 3.3. Success Rates for Phase Transition and Clinical Approval Probabilities
by Therapeutic Class for Self-originated Compounds First Tested in
Humans from 1993 to 2004
Medicines in Development: Selected Disease Categories
Table 3.4. Medicines in Clinical Trials for Skin Diseases (2011)
Table 3.5. Medicines in Clinical Trials for Arthritis (2011)
Table 3.6. Medicines in Clinical Trials for Leading Chronic Diseases
Affecting Medicare Beneficiaries (2013)
Table 3.7. Medicines in Clinical Trials for Mental Illnesses (2012)
Table 3.8. Medicines in Clinical Trials for Cancer (2012)
Table 3.9. Medicines in Clinical Trials for Neurological Disorders (2013)
Table 3.10. Medicines in Clinical Trials for Parkinson’s disease (2011)
Table 3.11. Biologics in Clinical Trials, by Product Category (2013)
Table 3.12. Biologics in Clinical Trials, by Target Disease (2013)
New Drug Approvals
Table 3.13. Number of New Therapeutics and Biologics Approvals and
Average Approval Times (2001-2011)
Table 3.14. New Drugs Approved in 2011, by Therapeutic Category
Table 3.15. Important Medicines Approved in 2011 for Ten Conditions
Table 3.16. Companies Winning Prix Galien Medals for Pharmaceutical
Excellence, 1970 - 2013
Table 3.17. Origin of Innovative New Drugs Approved, 1998- 2007
Table 3.18. Number of New Small Molecule Drug Approvals Per Year
Compared to New Biologic Drug Approvals (1988-2008)
Table 3.19. Drugs Withdrawn from the Market, 1950s-2010
Biotechnology Innovation
Table 3.20. History of Biotechnology: 500 B.C. – 2010
Table 3.21. Early Biotech and Drug Company Biologics Approvals
Table 3.22. Manufacturing Process for a Typical Recombinant Biotechnology Product
Table 3.23. Genetic Tests for Five Types of Cancer
Table 3.24. From Nature to Medicine: Biotechnology Drug Therapies
Table 3.25. Well-Known Pairs of Gene-Drug Pharmacogenomic Relationships
Table 3.26. Selected Personalized Medicine Drugs, Treatments and Diagnostics
Improvements in Health Outcomes from Pharmaceutical Therapy
Table 3.27. Pharmaceutical Innovation in Management of Heart Attack
and Stroke (1970s- 2000s)
Table 3.28. Improved Health Outcomes in Heart Attack and Stroke Resulting
from Key Advances in Pharmaceuticals
Table 3.29. Dollar Value of Pharmaceutical Treatment in Heart Attacks and Stroke
Chapter 4. Medication Use and Expenditures in the U.S. Population
Overview
Table 4.1. Top Prescribed Drugs by Total Expenditures and Number of Persons
with Expenditures, 2007
Table 4.2. Top Therapeutic Classes by Total Expenditures and Number of
Persons with Expenditures, 2007
Table 4.3. Prescription Drug Expenditures in the 10 Largest States, 2007
Table 4.4. Average Number of Total and Unique Prescriptions by Select
Person Characteristics, 2006
Table 4.5. Average Age of Patients Receiving Drug Classes
Table 4.6. Characteristics of Persons Purchasing Drugs from Mail Order
Pharmacies vs. Characteristics of Persons Purchasing Drugs from
Other Outlets, 2005 105
Table 4.7. Disparities in Pharmaceutical Treatment of Hispanic Patients
Table 4.8. Percentage of Persons Unable to Receive or Delayed in Receiving
Needed Medical Care, Dental Care, or Prescription Medicines, 2007
Table 4.9. Prescription Drug Estimates for Medicare Beneficiaries, 2005 and 2006
Table 4.10. The Top Five Therapeutic Classes of Outpatient Prescription
Drugs Used by Adults, 2006 and 2010
Table 4.11. The Top Five Therapeutic Classes of Outpatient Prescription Drugs
Used in the Medicare Population, 2006 and 2010
Table 4.12. Selected Prescription Drug Classes Used in the Past 30 Days, By Sex
and Age: Selected Years 1988 – 1994 through 2005-2008
Table 4.13. Allergic Rhinitis Agents: Trends in Use and Expenditures, 2000 and 2005
Table 4.14. Antiparkinson Agents: Trends in Use and Expenditures, 1996 and 2007
Table 4.15. Antipsychotics: Trends in Use and Expenditures, 1997 and 2007
Table 4.16. Antipsychotics: Disparities in Prescribing for African Americans
Table 4.17. Anticoagulants: Use and Expenditures, 2007
Table 4.18. Antidepressants: Trends in Use and Expenditures, 1999 and 2009,
and 1997 and 2002
Table 4.19. Asthma Agents: Total Medical and Prescription Expenditures by
Asthma Status and Whether Preventive Medicine Is Being Taken, 2006
Table 4.20. Asthma Agents: Preventive Medicine in 2006 -- Who Takes Them?
Table 4.21. Asthma Agents: Underuse of Medications and Disparities in Medication
Use in Childhood Asthma
Table 4.22. Analgesics: Trends in Outpatient Use and Expenditures, 1996 and 2006
Table 4.23. Arthritis Agents: Use and Expenditures, 2005
Table 4.24. Attention-Deficit Hyperactivity Disorder (ADHD) Agents: Use and
Expenditures in Children Ages 5-17, 2007
Table 4.25. Diabetes Management: Tests, Treatments and Trends, 2007
Table 4.26. Gastrointestinal Agents: Use and Trends, 1997 and 2007
Table 4.27. Thyroid Agents: Trends in Outpatient Use and Expenditures, 1996 and 2007
Chapter 5: United States Health Information
Overview
Prescription Medications
Table 5.1. Retail Prescription Drug Sales, 1995 to 2010
Table 5.2. Prescription Drug Classes Used in the Past 30 Days by Sex, 1988 – 1994
through 2005 – 2008
Table 5.3. Prescription Drug Classes Used in the Past 30 Days by Age, 1988 – 1994
through 2005 – 2008
Healthcare Expenditure
Table 5.4. Average Annual Healthcare Expenditure per Consumer Unit
by Age: 2007 to 2009
Table 5.5. Average Annual Healthcare Expenditure per Consumer Unit
by Education: 2007 to 2009
Table 5.6. Average Annual Healthcare Expenditure per Consumer Unit
by Income: 2007 to 2009
Table 5.7. Healthcare Expenditure by Type of Expenditure and Source
of Funds, Summary: 1960 to 2009
Medicaid/Medicare/Uninsured
Table 5.8. Distribution of Medicaid Enrollees by Enrollment Group by
States, Fiscal Year 2010
Table 5.9. Distribution of Medicare Beneficiaries by Race/Ethnicity
by States, 2010-2011
Table 5.10. People without Health Insurance for the Entire Year,
2008 and 2009
Table 5.11. Medicaid Pharmacy Supplemental Rebate Agreements
Table 5.12 Medicaid Coverage of Part D Cost Sharing Requirements
for Lower-Income Medicare Beneficiaries
Table 5.13 Medicaid Managed Care Drug “Carve out” Data
Table 5.14 State Reported Actions Necessary to Implement DRA
Medicaid Pharmacy Changes
Table 5.15 Flexibility Granted by DRA to States to Craft Medicaid
Pharmacy Policy
Table 5.16 Use of Medicaid Medication Management Programs
Table 5.17 Medicaid Prescription Reimbursement
Healthcare Revenue/ Employment
Table 5.18. Annual Revenue for Health Care Industries: 2007 to 2009
Table 5.19. Employment in the Health Service Industries, 1990 to 2010
Table 5.20. Physician Compensation by specialty, 2012
Table 5.21 Physician Compensation by geographical area, 2012
Table 5.22 Physician Compensation by practice setting, 2012
Table 5.23 Number of patient visits per week to Physician Office, 2012
Table 5.24 Amount of time spent with each Patient by Physicians, 2012
Chapter 6. Pharmaceutical Information and Education Resources
Pharmaceutical Information: Journals, Books, Magazines, and Internet Resources
Overview
Journals
Table 6.1. Descriptions of Some Top Pharmaceutical Journals (Selected)
Table 6.2. Rank Order of Pharmaceutical Journals with Impact Factors
for 2012 Greater than 1.00
Table 6.3. Expert Opinion Journals in Pharmacology and Drug Development
from Informa Healthcare
Table 6.4. Open Access Online Pharmaceutical Journals from OMICS
Group International
Table 6.5. Top Open-Access Online Pharmacy and Pharmacology Journals
with Impact Factor 5.067 to 1.162
Books
Table 6.6. Pharmaceutical Books (Selected)
Table 6.7. Online Books from Wiley Online Library: Drug Formulation
and Delivery
Table 6.8. Online Books from Wiley Online Library: Clinical Pharmacology
& Therapeutics
Table 6.9. Online Books from Wiley Online Library: Basic Pharmacology
Table 6.10. Online Books from Wiley Online Library: Pharmacology &
Pharmaceutical Medicine (Selected Titles)
Table 6.11. Open-Access Books on Pharmaceuticals and Pharmacology
News and Information Resources
Table 6.12. Pharmaceutical Magazines, News and Information Services
Table 6.13. Pharmaceutical-related Web Sites
Pharmaceutical Educational Resources
Table 6.14. Universities with Medical Schools in the United States
Table 6.15. American Association of Colleges of Nursing’s list of accredited
Baccalaureate & Graduate Nursing Programs by States
Table 6.16. List of Pharmacy Schools in the World 201
Chapter 7. Worldwide Health Statistics
Overview
Population Statistics
Table 7.1. Populations by Country, 2012
Table 7.2. Unemployment Rates by Country
Table 7.3. GDP per Capita by Country, 2011
Table 7.4. Population Earning Less Than $1.25 per Day by Country
Life, Death and Disease
Table 7.5. Median Age by Country, 2012
Table 7.6. Life Expectancy at birth vs. at age 60 by Country, 1990 - 2011
Table 7.7. Death Rates per 1,000 Population by Country, 2013
Table 7.8. Mortality Rates from HIV/AIDS, Malaria and Tuberculosis per
100,000 Population by Country, 2000 - 2011
Table 7.9. Distribution of causes of death among children aged <5 years
old, 2000 - 2010
Table 7.10. Incidence and Prevalence Rates of HIV/AIDS, Malaria and
Tuberculosis per 100,000 Population by Country, 2000 - 2011
Table 7.11. Cases of Selected Infectious Diseases (Cholera, Diphtheria,
H5N1 Influenza, Japanese encephalitis, Leprosy, Malaria,
Measles, Meningitis, Mumps) by Country, 2011 - 2012
Table 7.12. Cases of Selected Infectious Diseases (Pertussis, Plague,
Poliomyelitis, Congenital Rubella Syndrome, Rubella, Neonatal
Tetanus, Tuberculosis, Yellow fever) by Country, 2011 – 2012
Health Expenditures and Health Care Resources
Table 7.13. Health Expenditures per Capita by Country, 2010
Table 7.14. Out-of-Pocket Health Expenditures by Country, 2010
Table 7.15. Hospital Beds per 10,000 Population by Country, 2005 - 2012
Table 7.16. Nurses and Midwives per 10,000 Population by Country, 2005 - 2012
Table 7.17. Physicians per 10,000 Population by Country, 2005 – 2012
Pharmaceutical Statistics
Table 7.18. Pharmaceutical Sales
Table 7.19. Pharmaceutical Employment
Author Biography
Albert I Wertheimer, PhD, MBA is a professor at Temple University School of Pharmacy where he teaches and conducts research in the health economics area. He is the author of 32 books and over 400 scientific and professional journal articles. He is a popular speaker and consultant who has had assignments in over 60 countries. His pharmacy degree was earned at the University of Buffalo, the M.B.A. from the State University of New York at Buffalo and his PhD from Purdue University. He completed a postdoctoral research fellowship at St. Thomas’ Hospital Medical School of the University of London (UK).
Richard Levy, MS, PhD is a pharmacologist who currently operates a consulting practice in the Washington DC area. Dr. Levy was Vice President for Scientific Affairs at the National Pharmaceutical Council where he directed research on the use and value of innovative pharmaceuticals in the health care system. He has authored over 100 publications in pharmacology, neurobiology, pharmacoeconomics, and health policy. Dr. Levy was a professor in the Department of Pharmacology at the University of Illinois College of Medicine in Chicago. He received postdoctoral training in neuropharmacology at the University of Illinois and a PhD from the University of Delaware.
Leo L.H. Lui, BS, PharmD is a recent Doctor of Pharmacy graduate of Temple University School of Pharmacy. Born in Hong Kong and raised in New York City, he earned his B.S degree in Pharmaceutical Sciences at the University of Sciences in Philadelphia and is currently a pediatric pharmacist at St. Christopher’s Hospital for Children. His past experiences include working as a research assistant at Temple University under Albert Wertheimer and as a pharmacy intern at Chestnut Hill Hospital in Philadelphia and at Memorial Sloan Kettering Cancer Center in Manhattan.
Events
Jan 12 2025 Abu Dhabi, UAE
Carrefour des Gestions Locales de L'eau
Jan 22 2025 Rennes, France
Jan 29 2025 Tokyo, Japan
Feb 05 2025 Nantes, France
Feb 16 2025 Kampala, Uganda